Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.

Tom HolvoetMarie TruyensCara De GalanHarald PeetersFrancisco Mesonero GismeroAinara ElorzaPaola TorresLiv VandermeulenAranzazu Jauregui-AmezagaRocio Ferreiro-IglesiasYamile ZabanaLaia Peries ReverterJeroen Geldof Triana Lobaton

Published in: Journal of clinical medicine (2024)

Ustekinumab and vedolizumab show comparable effectiveness and safety in the elderly IBD population. Elderly IBD patients have an increased risk for non-IBD hospitalizations and malignancy compared to the younger IBD population, with corticosteroid use as the main risk factor.

Keyphrases

patients with inflammatory bowel disease
ulcerative colitis
middle aged
community dwelling
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
risk factors
systematic review
peritoneal dialysis
patient reported